๐ Eli Lilly $LLY surges ~5% โ Mounjaro & Zepbound nearly hit $15B in a single quarter
Eli Lilly blew away Q2 2026 estimates: revenue surged 48% year-over-year to $22.97B (vs $20.73B expected) and EPS of $8.38 crushed the $6.07 consensus. Mounjaro and Zepbound alone are approaching $15B in quarterly sales. Management raised full-year revenue guidance to $85B-$87B. The GLP-1 machine keeps accelerating โ how high can Lilly go before the market has already priced in perfection? Not financial advice.
โก 20 buzzing
177 views
๐ 0 subscribed
